Tetsuro Ochi

Chuo, 1040045, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis.

Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis.

Journal: International journal of clinical oncology

Published: May 02, 2026

T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel.

T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel.

Journal: International journal of hematology

Published: January 19, 2026

Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma.

Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma.

Journal: International journal of clinical oncology

Published: January 09, 2026

Consideration of the natural history of BCL2-positive follicular lymphoma: based on tumor site, histological grade, and histological transformation rate.

Consideration of the natural history of BCL2-positive follicular lymphoma: based on tumor site, histological grade, and histological transformation rate.

Journal: Human pathology

Published: October 26, 2025

Differential Expression of CD79B, CD19, and PD-L1 in de Novo and Transformed CD20-Negative Large B-Cell Lymphomas.

Differential Expression of CD79B, CD19, and PD-L1 in de Novo and Transformed CD20-Negative Large B-Cell Lymphomas.

Journal: Hematological oncology

Published: September 29, 2025

Schizophyllum commune infection following chimeric antigen receptor T-cell therapy in a patient with lymphoma.

Schizophyllum commune infection following chimeric antigen receptor T-cell therapy in a patient with lymphoma.

Journal: Journal of clinical and experimental hematopathology : JCEH

Published: September 28, 2025

Real-world effectiveness and safety of lisocabtagene maraleucel for relapsed/refractory large B cell lymphoma in Japan.

Real-world effectiveness and safety of lisocabtagene maraleucel for relapsed/refractory large B cell lymphoma in Japan.

Journal: International journal of clinical oncology

Published: August 31, 2025

Correlation with CD79B expression and clinicopathological parameters including cell of origin, CD79A and CD19 expression, and CD79B mutation in diffuse large B-cell lymphoma.

Correlation with CD79B expression and clinicopathological parameters including cell of origin, CD79A and CD19 expression, and CD79B mutation in diffuse large B-cell lymphoma.

Journal: Human pathology

Published: April 03, 2025

Clinicopathological differences between T-lymphoblastic leukemia/lymphoma, early T-precursor lymphoblastic leukemia/lymphoma, and mixed-phenotype acute leukemia with T lineage: An analysis of 41 adult cases.

Clinicopathological differences between T-lymphoblastic leukemia/lymphoma, early T-precursor lymphoblastic leukemia/lymphoma, and mixed-phenotype acute leukemia with T lineage: An analysis of 41 adult cases.

Journal: Human pathology

Published: May 11, 2024

Role of aberrant RNA splicing in acquired sideroblastic anemia

Role of aberrant RNA splicing in acquired sideroblastic anemia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: April 29, 2024

Heterogeneity or change in cell of origin in diffuse large B-cell lymphomas determined using hans algorithm.

Heterogeneity or change in cell of origin in diffuse large B-cell lymphomas determined using hans algorithm.

Journal: Human pathology

Published: April 16, 2024

Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.

Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.

Journal: Virchows Archiv : an international journal of pathology

Published: October 13, 2023

Showing 1-12 of 19

Last Updated: 09/26/2026